NCT01557777

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).

Detailed description

This is an open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).

Conditions

• Chronic Lymphocytic Leukemia

Interventions

Type	Name	Description
DRUG	Navitoclax	QD

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2012-03-20
• Last updated: 2014-07-04

Locations

15 sites across 5 countries: United States, Australia, Israel, Poland, Ukraine